Navigation Links
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Date:1/12/2009

PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company's Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey's Perforomist(R) Solution, and its term extends until June 22, 2021. The patent will be listed in the "Orange Book," giving Dey four Orange Book-listed patents covering Perforomist Solution.

U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and Jan. 6, 2009, respectively. These patents are directed to compositions of "R-formoterol," a specific form of the formoterol molecule, and their use.

In addition, Dey has received a "Notice of Allowance" on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey's already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey's IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana(R) product."

Dey also has additional pending U.S. patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.

Mylan Inc., which provides products to customers in mo
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
2. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
3. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
4. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
5. Procter & Gamble Reaches Settlement on Patent Infringement Lawsuit
6. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. FreePatentsOnline Launches the CitePatents Program : Making it Easy for Bloggers and Journalists to Reference Patents, and Add Patent Search to Websites
9. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
10. Kidnapped senior needed IU-patented home security system
11. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest healthcare ... lab testing and precision medicine solutions that can help pharmacists and other healthcare ... than 8.6 million adverse drug events are reported in the U.S. Pharmacogenetic ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... the largest online retailer of nutritional supplements, has officially opened the polls ... 11 awards in the following categories:, ,     Brand of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Over 400 personnel of the Central Reserve Police Force (CRPF), ... to drugs and alcohol// , according to an internal survey. ... number of men who have become drug dependent and found ... ,He said the survey was started in February ...
... There appears to be no conclusive proof that ... researchers from the American Cancer Society//. This is ... ,Though many medical specialists still prescribe vitamins ... Jacobs, senior epidemiologist and vitamin specialist with the ...
... There is no need for a malaria hospital in Kolkata ... L Joshi, Director of National Vector Born Disease Control Programme. ... dengue and malaria, Joshi said last year in Kolkata only ... the corresponing year was 73., ,Reprentatives of UP, Bihar, ...
... patients who would have to fork out much less ... Merck and Pfizer losing// their patent on drugs commanding ... Ranbaxy and Dr Reddy's Laboratories are being touted as ... vacuum created by the patent expiry of two biggest ...
... for Genetic Engineering and Biotechnology (CIGB) has registered the ... production of an anti-hepatitis B vaccine. // ... a true world scientific breakthrough, and it was obtained ... process required for it. , ,At a press ...
... new study, men with prostate cancer are more influenced ... //from trusting on clinical trial evidences. ... and comparing the anecdotal experiences of others with prostate ... treatment options were entirely different from them are the ...
Cached Medicine News:Health News:Misconception on Treatment Options among Prostate Cancer Patients 2
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... presented at ASCO with cediranib - a selective,VEGF signaling ... progression- free at six months(1), CHICAGO, June 04, 2007 ... presented today at,the annual meeting of the American Society ... recurrent glioblastoma (GBM),an invasive form of brain tumor with ...
... Follicular Lymphoma Reported,Today at ASCO Annual Meeting, ... plc,announced today long-term efficacy data from a ... of frontline treatment with the BEXXAR(R),Therapeutic Regimen ... with newly diagnosed advanced follicular non-Hodgkin's,lymphoma (NHL). ...
Cached Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7
Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
... Medical Spanish pocket plus for PDA is ... PDA and the Medical Spanish Dictionary pocket for ... plus for PDA provides an overview of the ... phrases, as well as basics of anatomy and ...
Taber's Cyclopedic Medical Dictionary is published by F.A. Davis. Contains approximately 56,000 terms....
This portable resource provides definitions for medical acronyms and abbreviations....
Medicine Products: